cost-benefit considerations for tki selection in cml
Published 1 year ago • 147 plays • Length 1:39Download video MP4
Download video MP3
Similar videos
-
1:24
considerations for tki choice in frontline and r/r cml
-
6:22
efficacy & tolerability of available tki therapies in cml & managing tki resistance
-
2:17
current cml treatments: which tki to choose?
-
1:16
mechanisms of resistance to the tki asciminib in cml
-
1:39
emerging therapeutic approaches for tki-resistant cml
-
1:22
unmet needs in cml: increasing treatment-free remission & accessibility to tkis
-
3:20
the current standard of care in cml and insights into the use of first- and second-generation tkis
-
6:31
an overview of trials investigating asciminib in the treatment of ph cml
-
13:24
chronic myeloid leukemia made easy
-
8:00
jorge cortes, md, shares data on asciminib versus tkis in cml
-
1:23
mechanical forces in the cll microenvironment and the importance of modeling them in vitro
-
0:58
asciminib has the potential to succeed where other tkis have failed in cml
-
1:03
bosutinib: a new, safer tki for frontline cml
-
3:18
predictors for tfr in cml: response duration, secondary treatment & frontline tki choice
-
1:46
benefits of second generation tkis for cml in the frontline
-
2:27
ascembl: asciminib versus bosutinib in third-line treatment of cp-cml
-
3:17
how can we improve the cost-effectiveness of aml treatment?
-
4:27
cml management in resource limited countries
-
0:57
potential approval of quizartinib in aml & its place in the aml treatment regimen
-
2:12
5-year update of bfore: bosutinib vs imatinib in cml
-
4:25
metabolic vulnerabilities in cml & the impact of tkis on glucose anaplerosis
-
1:05
personalized therapy in leukemia: a case study